HBM Healthcare Investments

As a venture capital company, HBM BioVentures is invested globally in some 40 mature emerging companies in the biotechnology/human medicine, diagnostics and medical technology sectors. The primary products of HBM BioVentures' portfolio companies are either at an advanced stage of development or already available on the market. The company focuses on unquoted emerging companies, with two-thirds are invested in private companies that offer high value creation potential. This has enabled HBM BioVentures to carve out a unique and distinctive market position. HBM BioVentures has a broad shareholder base and is listed on the SIX Swiss Exchange (ticker: HBMN).

HBM Healthcare Investments, established in 2001 and headquartered in Zug, Switzerland, Europe., specializes in Late Stage Venture, Early Stage Venture, Private Equity, Seed investments across Biotechnology, Health Care, Medical, Medical Device, Financial Services, Venture Capital, Finance, Health Diagnostics, Life Science, Genetics. The organization boasts a portfolio of 245 investments, with an average round size of $55.8M and 73 successful exits. Their recent investments include Broncus Technologies, Menlo Ventures, Abingworth, Genizon BioSciences, Investissement Desjardins. The highest investment round they participated in was $1412.1B. Among their most notable exits are Broncus Technologies and Menlo Ventures. Explore their portfolio in detail, see who is connected to them, and find their contact information on our platform.